ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

tedizolid phosphate

Also written as “TR-701 FA”, “Tedizolid phosphate” and “TR-701 FA 200 mg”.

Its studies are mostly in Skin Diseases, Bacterial · Bacterial Infections · Gram-Positive Bacterial Infections · Pneumonia · Skin Diseases, Infectious, led by 3 companies.

Drug pageTedizolid phosphate: every studyAll 29 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jul 23, 201027 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merckits history only250 open or runningphase 3since Jul 23, 2010Apr 23, 2008none ahead
Bayer10 open or runningphase 3since Oct 18, 2013Oct 18, 2013none ahead
Dong-A STits history only10 open or runningphase 1since Mar 24, 2014Mar 24, 2014none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Bayer only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 18, 2013First study: phase 3 study in Skin Diseases, InfectiousFirst studyNCT01967225 · 125 enrolled · Japan

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Bacterial 70S ribosome inhibitor”ChEMBL 37, by rule

Studies

The one study Bayer leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01967225Skin Diseases, Infectious · Japan3CompletedOct 28, 2016125

How it is read

Names in the registry

  • “TR-701 FA”, 9 entries
  • “Tedizolid phosphate”, 2 entries
  • “TR-701 FA 200 mg”, 2 entries
  • “IV Tedizolid Phosphate”, 1 entry
  • “Tedizolid Phosphate Oral Formulation 1 (Reference)”, 1 entry

Codes read as this program: TR701.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.